Q3 Earnings Forecast for Neurogene Issued By Leerink Partnrs

Neurogene Inc. (NASDAQ:NGNE) – Investment analysts at Leerink Partnrs cut their Q3 2025 earnings per share (EPS) estimates for shares of Neurogene in a research note issued on Monday, August 11th. Leerink Partnrs analyst M. Foroohar now anticipates that the company will post earnings of ($1.18) per share for the quarter, down from their previous estimate of ($1.14). The consensus estimate for Neurogene’s current full-year earnings is ($4.27) per share. Leerink Partnrs also issued estimates for Neurogene’s Q4 2025 earnings at ($1.30) EPS, FY2025 earnings at ($4.61) EPS and FY2026 earnings at ($5.97) EPS.

Neurogene (NASDAQ:NGNE) last posted its earnings results on Monday, August 11th. The company reported ($1.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.15) by $0.10.

Several other equities analysts have also recently weighed in on the company. BMO Capital Markets reiterated an “outperform” rating and set a $26.00 price objective (up previously from $22.00) on shares of Neurogene in a report on Thursday, June 12th. Robert W. Baird cut Neurogene from an “outperform” rating to a “neutral” rating and cut their price objective for the company from $38.00 to $24.00 in a report on Friday, May 16th. HC Wainwright cut their price objective on Neurogene from $50.00 to $45.00 and set a “buy” rating on the stock in a report on Tuesday, May 13th. Craig Hallum assumed coverage on Neurogene in a report on Tuesday, June 17th. They set a “buy” rating and a $50.00 price objective on the stock. Finally, Baird R W cut Neurogene from a “strong-buy” rating to a “hold” rating in a report on Friday, May 16th. Two analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $46.17.

Neurogene Trading Down 4.3%

Neurogene stock opened at $20.20 on Thursday. The firm has a market capitalization of $288.25 million, a P/E ratio of -4.69 and a beta of 1.69. Neurogene has a 1 year low of $6.88 and a 1 year high of $74.49. The business has a 50-day moving average of $20.36 and a 200-day moving average of $17.24.

Institutional Trading of Neurogene

Large investors have recently modified their holdings of the stock. Virtus ETF Advisers LLC lifted its position in shares of Neurogene by 45.1% during the 4th quarter. Virtus ETF Advisers LLC now owns 3,183 shares of the company’s stock worth $73,000 after buying an additional 989 shares during the last quarter. PNC Financial Services Group Inc. lifted its position in shares of Neurogene by 43.6% during the 2nd quarter. PNC Financial Services Group Inc. now owns 4,055 shares of the company’s stock worth $61,000 after buying an additional 1,232 shares during the last quarter. GAMMA Investing LLC lifted its position in shares of Neurogene by 2,985.1% during the 1st quarter. GAMMA Investing LLC now owns 4,134 shares of the company’s stock worth $48,000 after buying an additional 4,000 shares during the last quarter. Wells Fargo & Company MN lifted its position in shares of Neurogene by 34.5% during the 4th quarter. Wells Fargo & Company MN now owns 5,444 shares of the company’s stock worth $124,000 after buying an additional 1,397 shares during the last quarter. Finally, Corebridge Financial Inc. lifted its position in shares of Neurogene by 13.8% during the 1st quarter. Corebridge Financial Inc. now owns 5,826 shares of the company’s stock worth $68,000 after buying an additional 705 shares during the last quarter. 52.37% of the stock is owned by institutional investors and hedge funds.

Neurogene Company Profile

Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.